Analysis · matchups · November 20, 2026
Which GLP-1 provider matchups changed in November 2026?
Released: Last reviewed:
Between our October 15 and November 20, 2026 reads, no head-to-head winner flipped on compounded tirzepatide or semaglutide. NexLife and Eden became tied at $129, Found’s $20 cut narrowed seven tirzepatide gaps and widened one, and 18 tirzepatide matchups lost a like-for-like price while 18 gained one.
Takeaway: Before trusting any "X vs Y" verdict, check that both programs still publish a standing month-to-month price. On November 20, 2026 only 60 of our 427 older tirzepatide matchups (14%) had one on both sides.
How we compared
This site publishes head-to-head pages for pairs of GLP-1 telehealth programs. On October 15, 2026 there were 427 of them. On November 20, 2026 we read every program's own pricing pages again, the same way: the monthly price a new patient pays on the shortest recurring plan, plus any membership or program fee that is required. We call that the standing month-to-month all-in price. Starting-at prices, promo codes, first-month offers and prepaid packages are recorded but kept out of the comparison, because they do not describe the bill you get in month three.
For each matchup and each molecule we asked three questions. Did both programs have a standing price on both dates? If so, which one was lower, and by how much? And if one side gained or lost a standing price, was that because the program changed its prices, because we classified an unchanged price differently, or because we could not read the site? A matchup only has a like-for-like verdict when both sides publish a standing price for the same molecule.
The headline numbers
No winner flipped. On tirzepatide, 25 comparable matchups kept the same verdict and the same gap, 16 kept the verdict with a different gap, and one turned into a tie. Semaglutide looks similar: 27 unchanged, 17 with a moved gap, no ties and no flips.
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Same verdict, same gap | 25 | 27 |
| Same verdict, gap moved | 16 | 17 |
| Verdict became a tie | 1 | 0 |
| Winner flipped | 0 | 0 |
| Gained a like-for-like price | 18 | 19 |
| Lost a like-for-like price | 18 | 31 |
| Not comparable on either date | 349 | 333 |
| Total | 427 | 427 |
Source: our dataset of October 15 and November 20, 2026 (providers.json); a matchup is comparable when both programs print a standing month-to-month all-in price for that molecule.
| Molecule | October 15, 2026 | November 20, 2026 |
|---|---|---|
| Tirzepatide | 60 | 60 |
| Semaglutide | 75 | 63 |
The movement is in the bottom rows. 18 tirzepatide matchups gained a like-for-like price and 18 lost one, so the number of comparable tirzepatide matchups ended where it started, at 60. For semaglutide, 19 gained and 31 lost, a fall from 75 to 63. Most matchups, 349 on tirzepatide, still have at least one side with no standing price at all.
Where comparable matchups came from
Only one program in these matchups started charging a new standing tirzepatide price: Fifty 410 replaced its three-month starter bundle with a 4-week program at $199. That alone made 11 tirzepatide matchups comparable. The other 7 came from Rift, whose prices did not change; we explain that reclassification below. Every semaglutide gain came from the two reclassifications.
| Program | Tirzepatide Oct 15 | Tirzepatide Nov 20 | Semaglutide Oct 15 | Semaglutide Nov 20 | Why |
|---|---|---|---|---|---|
| Found | $359 | $339 | $289 | $269 | Price change: cash-pay cut; 12-month cycles now $199 tirzepatide, $149 semaglutide. |
| Fifty 410 | — | $199 | $199 | $199 | Price change: a 4-week tirzepatide program at $199 replaced the 3-month starter bundle. |
| Fridays | $359 | — | $249 | — | Price change: no month-to-month price printed; only promo-code and 12-month figures. |
| Gala Health | $199 | — | $199 | — | Price change: only "from $99" and "from $69" prices; plan set at checkout. |
| Rift | — | $219 | — | $199 | Reclassified: same prices as October; we now list its all-states monthly price as standing. |
| Noom Med | $299 | $299 | — | $249 | Reclassified (semaglutide): same $249 as October; we now list it as standing. |
| MEDVi | — | — | $299 | not re-read | Prices did not render for our reader on November 20. |
Why some stopped being comparable
Fridays no longer prints a month-to-month price on its pricing page. On November 20 it showed "as low as" $99 tirzepatide and $69 semaglutide with promo codes, and $240 and $150 a month on 12-month plans. Those figures are real, but they are not a standing monthly bill, so its 11 tirzepatide matchups that were comparable in October are not comparable now.
Gala Health moved from a single $199 price for both molecules to "from $99" and "from $69", with the final price set at checkout. MEDVi's prices did not render for our reader, so its semaglutide matchups are marked as not re-read rather than compared on an October figure. In October, 12 programs in our index had a standing tirzepatide price; on November 20 there are 13: Yucca Health (readable again), Fifty 410 and Rift joined, and Fridays and Gala Health left.
Both programs that stopped now lead with a lower conditional figure. Fridays' $99 code price for tirzepatide is $141 a month below the $240 it prints for a 12-month plan, and Gala Health's "from $69" semaglutide sits $130 below its October standing price of $199. Neither tells you what a full year costs, which is why we keep them out of the verdicts and show them, labelled, beside the standing prices on each matchup page.
What we reclassified, and why
Two changes in this re-read are ours, not the programs'. Rift's monthly prices were the same in October and November: $179 through one pharmacy in listed states, $219 through OptioRx in all 50 states, $249 through Hallandale. In October we listed none of them as standing; now we list the all-states $219 monthly price as Rift's standing tirzepatide price and $199 for semaglutide, and keep the cheaper state-limited options beside them. Noom Med's semaglutide program showed $249 a month after the first 4 weeks on both dates; we had left it unpriced in October, when its pages already disagreed ($249 on the pricing page and FAQ, $279 in a product-page footnote), and we now list the $249.
We also applied the starting-at rule more strictly: IVIM Health ("starting at" $117 plus a $75 monthly program fee) and Goby Meds (single months from $299, rising with dose) stay conditional, as they were in October.
The gaps that moved
Found cut its cash-pay tirzepatide from $359 to $339 a month and its 12-month cycle price from $239 to $199. That narrowed the seven gaps where Found was the more expensive side. Eden versus Found went from a $230 monthly gap to $210. Because Found bills every 28 days, a year is 13 cycles: 13 × $339 = $4,407, against 12 × $129 = $1,548 at Eden, a difference of $2,859. The one gap that widened is Found versus Remedy Meds, where Found was already the cheaper side: $40 in October, $60 now.
NexLife's price change on November 6 moved its own matchups. Its month-to-month tirzepatide went from $169 to $129, which turned NexLife versus Eden into a tie at that price, widened NexLife's lead over seven other comparable programs by $40 a month, and widened it over Found by $20, since Found also cut. The NexLife profile records the change and the date.
Matchups we restored
In October, Yucca Health's site blocked our reader and its 32 matchups were redirected to the programs' profiles. On November 20, 2026 its own help-center price article was readable, so the pages are back. Yucca Health lists $139 for tirzepatide, $10 more than Eden, and $89 for semaglutide, $10 less. Its 12-month plans, $119 and $69 a month, are paid upfront: $1,428 and $828.
12 of the restored pairs have a like-for-like tirzepatide price and 12 a like-for-like semaglutide price. Across all 459 matchups now published, that makes 72 comparable on tirzepatide and 75 on semaglutide.
What this means for you
- Treat a verdict as dated. A head-to-head is only as current as both price reads. If one side stops printing a standing price, the verdict lapses even when nothing else changed.
- Ask for the bill in month three. Promo codes and "from" prices can be far below the standing price. Fridays' code price is $99 against $240 on its 12-month plan.
- Add every required fee. IVIM Health's $75 program fee turns a $117 starting price into $192.
- Check your pharmacy and state. Programs like Rift price by pharmacy; the figure in an ad may not be available where you live. Our guide to pharmacy- and state-dependent pricing explains how to compare them.
- Count billing cycles. Programs billed every 28 days charge 13 times a year, which adds a month's price to any yearly comparison.
Brand-name medication is outside these matchups. Lilly and Hims & Hers said on November 6 that Zepbound and Foundayo are available on the Hims platform at Lilly's self-pay prices, starting at $299 and $149 a month, which does not change any compounded comparison here. The full list of matchups is on the comparison index, and each program's figures are on its profile, for example Found and Fifty 410.
Limits of this analysis
We read public pricing pages; we did not complete checkouts, so a fee added inside an intake flow would escape us. Six programs blocked our reader on November 20 and are counted as not re-read. A verdict here is about price only; it says nothing about clinical care, which a licensed clinician should judge. Compounded tirzepatide and semaglutide are not FDA-approved, and FDA's April 30, 2026 proposal on 503B bulk compounding still had no final decision on November 20, 2026.
Sources
- Our price dataset, October 15 and November 20, 2026 reads (CC BY 4.0) · read 2026-11-20
- Found compounded tirzepatide pricing · joinfound.com · read 2026-11-20 source
- Fifty 410 tirzepatide pricing · fifty410.com · read 2026-11-20 source
- Fridays pricing · joinfridays.com · read 2026-11-20 source
- Gala Health tirzepatide page · galaglp1.com · read 2026-11-20 source
- Rift pricing (site code) · joinrift.com · read 2026-11-20 source
- Noom Med pricing · noom.com · read 2026-11-20 source
- Yucca Health plan pricing article · intercom.help · read 2026-11-20 source
- NexLife tirzepatide plans · nexlife.us · read 2026-11-20 source
- Lilly and Hims & Hers release, November 6, 2026 · prnewswire.com · read 2026-11-20 source
- Federal Register: 503B bulks proposal, May 1, 2026 · federalregister.gov · read 2026-11-20 source
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026) · fda.gov · read 2026-11-20 source